This update includes information about the plans for introducing the new nine-valent human papillomavirus vaccine (HPV 9), the new meningococcal b vaccines, and an important reminder about using the IIS for monthly accountability reporting. Please share this information with staff in your clinics.
HPV 9 Transition Planning:
What’s happening now?
We will remove Gardasil (HPV 4) vaccine from provider order sets on April 1, 2015. We will allow urgent orders for HPV 4 during the month of April if a provider has less than 5-days’ stock on hand. Providers may contact their LHJ to place an urgent order for HPV 4 vaccine if needed. We will work with LHJs to process those orders.
Why are we placing this restriction on HPV 4 vaccine ordering?
- We expect HPV 9 to be available in May of 2015.
- Most providers have at least 30 to 45 days of HPV 4 in stock–many have 60 to 90 days–stock on hand. This is millions of dollars worth of vaccine.
- We all must work together to limit the waste of HPV 4 vaccine.
What will happen when HPV 9 is available?
Providers will start ordering HPV 9 using their regular EOQ order schedule in May. Providers may continue to use HPV 4 for male patients 16 through 18 years of age per the vaccine’s licensure. We will share more information about the use of HPV 9 for patients who started the HPV series with HPV4 when it is available.
Meningococcal B Vaccines:
The FDA recently licensed two meningococcal B vaccines. At this time, providers may buy the vaccines their manufacturers. The Advisory Committee on Immunization Practices voted on the use of these vaccines for very specific groups, and there is no routine recommendation at this time. The high risk groups indicated for vaccination are:
- Persistent complement component deficiencies
- Anatomic or functional asplenia
- Serogroup B outbreak
CDC has not yet made the vaccine available to the Vaccines for Children Program. CDC will limit the VFC supply to the high-risk groups. When CDC makes the vaccine available, we will incorporate it into the Washington Childhood Vaccine Program. We will share more about these vaccines as we learn more.
For more information about the vaccines:
- Trumenba – manufactured by Wyeth Pharmaceuticals – approved for ages 10 through 25.
- Bexsero – manufactured by Novartis Vaccines – approved for ages 10 through 25.
Online Accountability Reporting:
Almost 60% of providers participating in the Childhood Vaccine Program submit their monthly accountability reports online in the IIS. Congratulations to all of the practices that have transitioned to this efficient, paperless method of reporting! If your clinic isn’t reporting online yet, it’s time to get started! For more information, please visit our website: Childhood Vaccine Program. From the left menu bar, select “Online Accountability Reporting.”
View online videos that will help your clinic learn how to complete the process online. Scroll down to “Submit Inventory Reports Online.”